Incyte Corp Files 2023 Annual Report on Form 10-K

TL;DR

<b>Incyte Corp has submitted its 2023 10-K filing, detailing financial performance and corporate information.</b>

AI Summary

INCYTE CORP (INCY) filed a Annual Report (10-K) with the SEC on February 13, 2024. Incyte Corp filed its 10-K report for the fiscal year ending December 31, 2023. The report covers the period from January 1, 2023, to December 31, 2023. The company's principal executive offices are located in Wilmington, Delaware. Incyte Corp was formerly known as Incyte Genomics Inc. and Incyte Pharmaceuticals Inc. The filing includes financial data and operational details for the fiscal year 2023.

Why It Matters

For investors and stakeholders tracking INCYTE CORP, this filing contains several important signals. The 10-K filing provides a comprehensive overview of Incyte's financial health and strategic direction for the past fiscal year, crucial for investors assessing the company's stability and growth prospects. This annual report is a key document for understanding Incyte's product revenue streams, including sales from products, royalties, and milestone payments, which are vital indicators of its market performance and future potential.

Risk Assessment

Risk Level: — INCYTE CORP shows moderate risk based on this filing. The filing is a standard annual report (10-K) and does not contain immediate, significant negative news, but the inherent risks of the pharmaceutical industry, such as drug development failures and regulatory hurdles, are present.

Analyst Insight

Review the detailed financial statements and risk factors in the 10-K to assess Incyte's performance and potential future challenges.

Revenue Breakdown

Key Numbers

• 2023-12-31 — Fiscal Year End (CONFORMED PERIOD OF REPORT)
• 2024-02-13 — Filing Date (FILED AS OF DATE)
• 2023-01-01 — Reporting Period Start Date (2023-01-01)
• 2023-12-31 — Reporting Period End Date (2023-12-31)

Key Players & Entities

• Incyte Corp (company) — FILER
• Wilmington (location) — CITY
• DE (location) — STATE
• Incyte Genomics Inc (company) — FORMER COMPANY
• Incyte Pharmaceuticals Inc (company) — FORMER COMPANY

FAQ

Industry Context

Incyte Corp operates in the commercial physical & biological research sector, focusing on the development of novel therapeutics.

Regulatory Implications

The company is subject to standard SEC regulations for public companies, including the requirement to file annual reports on Form 10-K.

What Investors Should Do

1. Analyze the revenue breakdown by segment (Product, Royalty, Milestone & Contract Revenues) for 2023.
2. Review the company's financial statements, including balance sheets and income statements, for key performance indicators.
3. Examine the risk factors section for potential challenges and uncertainties facing Incyte in the upcoming fiscal year.

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K.
• 2024-02-13: Filing Date — Date the 10-K was officially filed with the SEC.

Year-Over-Year Comparison

This is the initial filing analyzed, so no comparison to a previous filing is available.

Filing Documents

• incy-20231231.htm (10-K) — 2075KB
• exhibit211-12312023.htm (EX-21.1) — 17KB
• exhibit231-12312023.htm (EX-23.1) — 4KB
• exhibit311-12312023.htm (EX-31.1) — 10KB
• exhibit312-12312023.htm (EX-31.2) — 10KB
• exhibit321-12312023.htm (EX-32.1) — 5KB
• exhibit322-12312023.htm (EX-32.2) — 5KB
• exhibit971-revisedclawback.htm (EX-97.1) — 26KB
• 0000879169-24-000045.txt (&nbsp;) — 11194KB
• incy-20231231.xsd (EX-101.SCH) — 76KB
• incy-20231231_cal.xml (EX-101.CAL) — 104KB
• incy-20231231_def.xml (EX-101.DEF) — 425KB
• incy-20231231_lab.xml (EX-101.LAB) — 1088KB
• incy-20231231_pre.xml (EX-101.PRE) — 750KB
• incy-20231231_htm.xml (XML) — 1505KB

Forward-Looking Statements

Forward-Looking Statements 2 Summary Risk Factors 5 PART I Item 1.

Business

Business 6 Item 1A.

Risk Factors

Risk Factors 36 Item 1B. Unresolved Staff Comments 62 Item 1C. Cybersecurity 63 Item 2.

Properties

Properties 63 Item 3.

Legal Proceedings

Legal Proceedings 64 Item 4. Mine Safety Disclosures 64 Information about our Executive Officers 64 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 67 Item 6. [ Reserved ] 67 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 67 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 76 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 77 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 116 Item 9A.

Controls and Procedures

Controls and Procedures 116 Item 9B. Other Information 119 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 119 PART III Item 10. Directors, Executive Officers and Corporate Governance 119 Item 11.

Executive Compensation

Executive Compensation 119 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 120 Item 13. Certain Relationships and Related Transactions, and Director Independence 120 Item 14. Principal Accountant Fees and Services 120 PART IV Item 15. Exhibits, Financial Statement Schedules 120 Item 16. Form 10-K Summary 123

SIGNATURES

SIGNATURES 123 1 Table of Contents

Forward-Looking Statements

Forward-Looking Statements This report contains forward-looking statements that involve risks and uncertainties. These statements relate to future periods, future events or our future operating or financial plans or performance. Often, these statements include the words "believe," "expect," "target," "anticipate," "intend," "plan," "seek," "estimate," "potential," or words of similar meaning, or future or conditional verbs such as "will," "would," "should," "could," "might," or "may," or the negative of these terms, and other similar expressions. These forward-looking statements include statements as to: the discovery, development, formulation, manufacturing and commercialization of our compounds, our drug candidates and JAKAFI /JAKAVI (ruxolitinib), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), MONJUVI (tafasitamab-cxix) / MINJUVI (tafasitamab), OPZELURA (ruxolitinib) cream and ZYNYZ (retifanlimab-dlwr); our plans to further develop our operations outside of the United States; conducting clinical trials internally, with collaborators, or with clinical research organizations; our collaboration and strategic relationship strategy, and anticipated benefits and disadvantages of entering into collaboration agreements; our licensing, investment and commercialization strategies, including our plans to commercialize our drug products and drug candidates; the regulatory approval process, including obtaining U.S. Food and Drug Administration and other international regulatory authorities' approval for our products in the United States and abroad; the safety, effectiveness and potential benefits and indications of our drug candidates and other compounds under development; the timing and size of our clinical trials; the compounds expected to enter clinical trials; timing of clinical trial results; our ability to manage expansion of our drug discovery and development operations; future required expertise relating to clinical trials, manufacturing, sales and marketing;

Business

Item 1. Business Overview Incyte is a global biopharmaceutical company engaged in the discovery, development and commercialization of proprietary therapeutics. Our global headquarters is located in Wilmington, Delaware, where we conduct discovery, clinical development and commercial operations. We also conduct clinical development and commercial operations from our European headquarters in Morges, Switzerland and our other offices across Europe, as well as our Japanese office in Tokyo and our Canadian headquarters in Montreal. We are focused in two therapeutic areas that are defined by the indications of our approved medicines and the diseases for which our clinical candidates are being developed. One therapeutic area is Hematology/Oncology, which comprises Myeloproliferative Neoplasms (MPNs), Graft-Versus-Host Disease (GVHD), solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity (IAI), which includes our Dermatology commercial franchise. We are also eligible to receive milestones and royalties on molecules discovered by us and licensed to third parties. Hematology and Oncology Our hematology and oncology franchise comprises five approved products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib) and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. JAKAFI (ruxolitinib) JAKAFI (ruxolitinib) is our first product to be approved for sale in the United States. It was approved by the U.S. Food and Drug Administration (FDA) in November 2011 for the treatment of adults with intermediate or high-risk myelofibrosis (MF); in December 2014 for the treatment of adults with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea; in May 2019 for the treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older; and in Septe

View Full Filing

View this 10-K filing on SEC EDGAR